Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement Post author:GHIAA Admin Post published:November 8, 2022 Post category: Continue ReadingGates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement Post author:GHIAA Admin Post published:November 8, 2022 Post category: Continue ReadingGates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement Post author:GHIAA Admin Post published:November 8, 2022 Post category: Continue ReadingGates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement Post author:GHIAA Admin Post published:September 28, 2022 Post category: Continue ReadingGilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
Shionogi – GARDP, Cefiderocol License Agreement Post author:GHIAA Admin Post published:July 8, 2022 Post category: Continue ReadingShionogi – GARDP, Cefiderocol License Agreement
Shionogi – GARDP, Cefiderocol License Agreement Post author:GHIAA Admin Post published:July 8, 2022 Post category: Continue ReadingShionogi – GARDP, Cefiderocol License Agreement
Shionogi – GARDP, Cefiderocol License Agreement Post author:GHIAA Admin Post published:July 8, 2022 Post category: Continue ReadingShionogi – GARDP, Cefiderocol License Agreement
University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement Post author:GHIAA Admin Post published:January 11, 2022 Post category: Continue ReadingUniversity of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
BMS – MPP Sublicense & Tech Transfer Agreement Post author:GHIAA Admin Post published:November 30, 2021 Post category: Continue ReadingBMS – MPP Sublicense & Tech Transfer Agreement